Our findings highlight that the treatment of CRSwNP patients in Taiwan or other countries with a similar COX-2 endotype may benefit from using a corticosteroid or a selective COX-2 inhibitor to improve COX-2-mediated inflammation and oxidative stress in nasal polyposis. Here, PTGS2 is linked to chronic rhinosinusitis with nasal polyps.